OncoSil Medical Earnings Call Transcripts

Fiscal Year 2026

FDA announcement

FDA granted HDE approval for OncoSil, the first Class III device for unresectable, non-metastatic distal cholangiocarcinoma, enabling U.S. marketing with initial use limited to five centers and 30 patients. Broader rollout and revenue depend on completing a post-approval study, with full launch targeted for the second half of FY 2027.

Read full transcript →